NCT07470476Not yet recruiting
Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease
Progression of NSCLC at All Stages of the Disease - Pathophysiological Mechanisms - Innovative Approaches to Translational Biology
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
This single-center observational cohort study conducted at Bordeaux University Hospital aims to establish a structured clinico-biological platform in non-small cell lung cancer (NSCLC) to investigate the biological mechanisms involved in tumor initiation, progression, and relapse across all disease stages (I-IV). A total of 150 consecutive adult patients with histologically or cytologically confirmed NSCLC will be included over a 3-year period. Tumor samples will undergo translational analyses. These biological data will be correlated with pseudonymized clinical data collected from medical records and the institutional clinical data warehouse. The primary objective is to characterize the molecular, metabolic, and immune mechanisms associated with tumor progression and recurrence in NSCLC. The central hypothesis is that integrating comprehensive clinical data with in-depth molecular and immunological analyses of tumor tissues will identify biologically distinct patterns associated with disease evolution, therapeutic resistance, and prognosis. Such integrated clinico-biological signatures may improve patient stratification and contribute to the identification of novel biomarkers and therapeutic targets in NSCLC.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 10 Mar 2026
- Start date
- Jun 2026
- Primary completion date
- Jun 2036
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Lung cancer
- NCT number
- NCT07470476
What you commit to
- Study type: Observational
- Planned participants: 150
- From Jun 2026 to the primary completion date, Jun 2036
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of any other malignancy other than NSCLC within 1 years prior to screening. except for non-melanoma skin cancers, in situ cancers, or low-risk prostate cancer
- Patients who are in a period of exclusion following another study or who have participated in another interventional study involving a medicinal product within 30 days prior to entry into the protocol or who are participating in another clinical study.
Other illness
- Patients with small cell lung cancer.
- Patients with a medical or psychiatric condition or illness that compromises their ability to understand the information or participate in the study.
Other
- Pregnant or breastfeeding women.
- Individuals subject to legal protection measures (legal guardianship, trusteeship or curatorship).
- Individuals deprived of their liberty by judicial or administrative decision.
- Individuals who are unable to give their consent.
Who the study is looking for
- Adult patients
- NSCLC treated at the Bordeaux University Hospital.
- TNM stage between I to IV
- Patient affiliated with or beneficiary of a social security scheme.
- Non opposition
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.